Who we are?

Pharmaseed is a GLP-certified pre-clinical and early clinical CRO specializing in translational and regenerative studies.

Pharmaseed is equipped for the execution of NCE studies, biologics and medical-devices as well as conducting and following through from the development stage until first-in-man trials. These studies include safety and efficacy evaluation in various animal models in addition to complementary in-vitro/ex-vivo models and on-site human anatomy services.

Pharmaseed’s expertise in preclinical studies lies mostly in the following areas:
Cardio/vascular, Immuno-Oncology, Stem cell and Cellular Therapeutics, Microbiome research, Infectious Diseases, and CNS.

Pharmaseed, established in 2003, is a GLP-certified contract research organization (CRO) revered for its cutting-edge pre-clinical, early clinical, and consulting services, tailored to the needs of the medical device, biotechnology, and pharmaceutical sectors. Operating from state-of-the-art facilities that boast advanced technology and a high-quality vivarium, we provide an environment where innovation and precision meet to foster the development of groundbreaking health solutions.

In our commitment to global reach and accessibility, we have expanded our footprint by opening a branch in the United States. This strategic addition not only brings us closer to our partners and clients across the U.S. but also enhances our ability to facilitate the seamless transformation of innovative ideas into tangible, market-ready health solutions.

Our expansion and collaborative approach position Pharmaseed as your preferred partner, offering unparalleled expertise and a unique blend of local presence with a global perspective, ready to navigate the complexities of bringing your vision to life.

All our services are priced at a competitive rate in comparison to European and U.S. based companies.

Why work with us?

Innovative technology requires an innovative CRO
Pharmaseed is Israel’s largest GLP - certified pre-clinical and early clinical CRO, specializing in translational projects of all stages, mastering the “end in mind” approach.
With over 20 years of experience, a professional team which includes over 13 PHD and postdoctoral level researchers who have held key positions within the life sciences industry, state of the art laboratory, in house vivarium, BL2 safety unit and a modern in vitro laboratory, we are conducting multidisciplinary, complex studies covering molecular, cellular and in vivo needs according to the highest ethical and regulatory standards.

During our 20 years of activity, we have learned how to adjust and balance creativity and flexibility, maintaining rigid ethics and quality demands.
Pharmaseed provides in depth knowledge and experience in planning and interpreting study results. We offer high end “one stop shop” R&D services, hence, multiplying the chances of transforming your product from a mere idea, to a real sustainable technology.

Safety & ADME

Toxicity studies investigate the safety profile of a candidate compound, as well as providing important information about the absorption, distribution, metabolism, and excretion (ADME) of the compound in the body. A candidate compound must be assessed in different kinds of non-clinical toxicity studies before it can be administered to the first human volunteer. Toxicology studies can be either single-dose or repeated-dose studies.
Whether your compound is an original small molecule or bioequivalent generic, injectable large molecule or biosimilar – our experts are true specialists.